199 related articles for article (PubMed ID: 15329424)
1. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.
Leonard MB; Feldman HI; Shults J; Zemel BS; Foster BJ; Stallings VA
N Engl J Med; 2004 Aug; 351(9):868-75. PubMed ID: 15329424
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids and bone mineral content in the childhood nephrotic syndrome.
Gulati S; Gulati K
N Engl J Med; 2004 Dec; 351(25):2655-7; author reply 2655-7. PubMed ID: 15602029
[No Abstract] [Full Text] [Related]
3. Glucocorticoids and bone mineral content in the childhood nephrotic syndrome.
Cooper MS; Stewart PM
N Engl J Med; 2004 Dec; 351(25):2655-7; author reply 2655-7. PubMed ID: 15609419
[No Abstract] [Full Text] [Related]
4. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome.
Ribeiro D; Zawadynski S; Pittet LF; Chevalley T; Girardin E; Parvex P
Eur J Pediatr; 2015 Jul; 174(7):911-7. PubMed ID: 25573461
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency.
Sahakitrungruang T; Wacharasindhu S; Supornsilchai V; Srivuthana S; Kingpetch K
J Med Assoc Thai; 2008 May; 91(5):705-10. PubMed ID: 18672636
[TBL] [Abstract][Full Text] [Related]
6. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
Rudge S; Hailwood S; Horne A; Lucas J; Wu F; Cundy T
Rheumatology (Oxford); 2005 Jun; 44(6):813-8. PubMed ID: 15695300
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral content in nephrotic children on long-term, alternate-day prednisone therapy.
Polito C; La Manna A; Todisco N; Cimmaruta E; Sessa G; Pirozzi M
Clin Pediatr (Phila); 1995 May; 34(5):234-6. PubMed ID: 7628164
[TBL] [Abstract][Full Text] [Related]
8. Markers of bone metabolism in children with nephrotic syndrome treated with corticosteroids.
Pańczyk-Tomaszewska M; Adamczuk D; Kisiel A; Skrzypczyk P; Przedlacki J; Górska E; Stelmaszczyk-Emmel A; Demkow U; Roszkowska-Blaim M
Adv Exp Med Biol; 2015; 840():21-8. PubMed ID: 25310960
[TBL] [Abstract][Full Text] [Related]
9. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.
Feber J; Gaboury I; Ni A; Alos N; Arora S; Bell L; Blydt-Hansen T; Clarson C; Filler G; Hay J; Hebert D; Lentle B; Matzinger M; Midgley J; Moher D; Pinsk M; Rauch F; Rodd C; Shenouda N; Siminoski K; Ward LM;
Osteoporos Int; 2012 Feb; 23(2):751-60. PubMed ID: 21494860
[TBL] [Abstract][Full Text] [Related]
10. Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: impact of the underlying disease.
Burnham JM; Shults J; Petit MA; Semeao E; Beck TJ; Zemel BS; Leonard MB
J Bone Miner Res; 2007 Apr; 22(4):551-9. PubMed ID: 17243860
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome.
Wetzsteon RJ; Shults J; Zemel BS; Gupta PU; Burnham JM; Herskovitz RM; Howard KM; Leonard MB
J Bone Miner Res; 2009 Mar; 24(3):503-13. PubMed ID: 19016583
[TBL] [Abstract][Full Text] [Related]
12. Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency.
Baroncelli GI; Bertelloni S; Ceccarelli C; Saggese G
J Clin Endocrinol Metab; 1998 Sep; 83(9):3150-4. PubMed ID: 9745418
[TBL] [Abstract][Full Text] [Related]
13. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.
Phan V; Blydt-Hansen T; Feber J; Alos N; Arora S; Atkinson S; Bell L; Clarson C; Couch R; Cummings EA; Filler G; Grant RM; Grimmer J; Hebert D; Lentle B; Ma J; Matzinger M; Midgley J; Pinsk M; Rodd C; Shenouda N; Stein R; Stephure D; Taback S; Williams K; Rauch F; Siminoski K; Ward LM;
Osteoporos Int; 2014 Feb; 25(2):627-37. PubMed ID: 23948876
[TBL] [Abstract][Full Text] [Related]
14. Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids.
Foster BJ; Shults J; Zemel BS; Leonard MB
Am J Clin Nutr; 2004 Nov; 80(5):1334-41. PubMed ID: 15531684
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy.
Cortet B; Flipo RM; Blanckaert F; Duquesnoy B; Marchandise X; Delcambre B
Rev Rhum Engl Ed; 1997; 64(7-9):451-8. PubMed ID: 9338926
[TBL] [Abstract][Full Text] [Related]
16. Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome.
Sbrocchi AM; Rauch F; Matzinger M; Feber J; Ward LM
Pediatr Nephrol; 2011 Jan; 26(1):139-42. PubMed ID: 20922433
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency.
Bachrach LK; Marcus R; Ott SM; Rosenbloom AL; Vasconez O; Martinez V; Martinez AL; Rosenfeld RG; Guevara-Aguirre J
J Bone Miner Res; 1998 Mar; 13(3):415-21. PubMed ID: 9525342
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral content deficits of the spine and whole body in children at time of diagnosis with celiac disease.
Jatla M; Zemel BS; Bierly P; Verma R
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):175-80. PubMed ID: 19179879
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in children with steroid-sensitive nephrotic syndrome.
Mishra OP; Meena SK; Singh SK; Prasad R; Mishra RN
Indian J Pediatr; 2009 Dec; 76(12):1237-9. PubMed ID: 19936659
[TBL] [Abstract][Full Text] [Related]
20. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
